関連する実験動画

Updated: Sep 9, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

ハルミンはDYRK1A媒介の超活性化RAS/MAPK阻害によって臓がんを抑制する

Cen Liu¹, Jinchai Qi¹, Danyang Ye¹

¹Beijing University of Chinese Medicine, Beijing 102400, China.

Biochemical pharmacology

|August 31, 2025

まとめ

双重特異性のチロシンリン酸化調節キナーゼ1A (DYRK1A) は,臓がんにおけるKRAS G12Dを調節する. ハルミンはDYRK1Aを阻害し,腫瘍の成長を抑制し,KRAS G12Dが誘発する癌の新たな治療標的を提供している.

科学分野:

腫瘍学
分子生物学
生物化学

背景:

KRAS G12D変異は,臓がん (PC) で一般的であり,腫瘍の成長を誘導する.
新興のKRAS G12D阻害剤は有効性を示しているが,耐性があるため,新たな治療戦略が必要である.
新しい標的を特定することは,耐性を克服し,PC治療の結果を改善するために不可欠です.

研究の目的:

PCにおけるKRAS G12D活性に対する二重特異性チロシンリン酸化調節キナーゼ1A (DYRK1A) の役割を調査する.
PCにおけるDYRK1Aを標的とする潜在的な治療薬として,ハーミン (HM) を調査する.
KRAS G12D/MAPK経路のDYRK1Aの調節に伴う分子メカニズムを解明する.

主な方法:

DYRK1Aのフォスファタゼ活性とKRAS G12D-GTPレベルへの影響を評価する生化学的測定
DYRK1A- KRAS G12Dの相互作用を確認するために,光コロカライゼーション,双分子光補充 (Bi- FC) と共免疫プレシピテーション (Co- IP) を行う.
HM治療によって誘発された遺伝子発現の変化を分析するためのRNAシーケンシング.
治療対象としてDYRK1Aを検証するためのCaenorhabditis elegansモデル

主要な成果:

DYRK1Aのノックダウンにより,KRAS G12Dの過剰活性化が抑制され,KRAS G12Dのレベルを調節する役割が示された.
ハルミン (HM) はDYRK1Aの阻害剤として特定され,KRAS G12D/ MAPKの活性が抑制され,PC細胞の悪性腫瘍が減少した.
DYRK1AとKRAS G12Dの間の直接的な相互作用が確認され,KRAS G12Dの活性化にDYRK1Aのキナーゼ活性が不可欠であった.
HM治療はRASに関連する経路遺伝子をダウン調節し,PC細胞における自殺を抑制する可能性があることを示した.
C. elegans の DYRK1A ホモログ (mbk - 1) の機能喪失変異は,KRAS G12D誘発のフェノタイプを抑制した.

結論:

DYRK1Aは,KRAS G12Dを活性化し,PCの進行を促進する上で重要な役割を果たします.
ハルミンは,DYRK1Aキナーゼの活性を抑制することによって,RAS/ MAPK経路を抑制する.
DYRK1Aは,KRAS G12Dによる臓がんに対する有望な治療標的である.

キーワード:

DYRK1A ハルミン臓がん RAS変異

さらに関連する動画

A Preclinical Murine Model of Hepatic Metastases

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

関連する概念動画

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...